BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Treatment
52 results:

  • 1. Tumor-infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California breast cancer Family Registry.
    Ransohoff JD; Miller I; Koo J; Joshi V; Kurian AW; Allison KH; John EM; Telli ML
    JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38547391
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
    Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
    BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory breast cancer-Treated with Neoadjuvant Systemic Therapy.
    De Schepper M; Nguyen HL; Richard F; Rosias L; Lerebours F; Vion R; Clatot F; Berghian A; Maetens M; Leduc S; Isnaldi E; Molinelli C; Lambertini M; Grillo F; Zoppoli G; Dirix L; Punie K; Wildiers H; Smeets A; Nevelsteen I; Neven P; Vincent-Salomon A; Larsimont D; Duhem C; Viens P; Bertucci F; Biganzoli E; Vermeulen P; Floris G; Desmedt C
    Cancer Res Commun; 2024 Jan; 4(1):186-199. PubMed ID: 38147006
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The clinical efficacy of Apatinib plus Ba Zhen granules in the treatment of advanced unresectable differentiated thyroid cancer and their influence on immune factors.
    Bai Y; Jin J; Liu Y; Zhang B; Li J
    Pak J Pharm Sci; 2023 May; 36(3(Special)):935-939. PubMed ID: 37587701
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genomics of
    Lipsyc-Sharf M; Jain E; Collins LC; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Come SE; Peppercorn JM; Borges VF; Warner E; Snow C; Krop IE; Kim D; Weiss J; Zanudo JGT; Partridge AH; Wagle N; Waks AG
    JCO Precis Oncol; 2023 Jun; 7():e2300076. PubMed ID: 37364233
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.
    Donnenberg VS; Luketich JD; Sultan I; Lister J; Bartlett DL; Ghosh S; Donnenberg AD
    Front Immunol; 2023; 14():1157697. PubMed ID: 37063842
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Mendelian Randomization Study on Causal Association of IL-6With breast cancer.
    Zhang M; Ma N; Wang R
    Clin Breast Cancer; 2023 Jun; 23(4):e182-e188. PubMed ID: 36813657
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative breast cancer.
    Nederlof I; Voorwerk L; Kok M
    Clin Cancer Res; 2023 Jul; 29(13):2362-2370. PubMed ID: 36622327
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Therapeutic yoga reduces pro-tumorigenic cytokines in cancer survivors.
    Patel DI; Almeida GJ; Darby NT; Serra MC; Calderon T; Lapetoda A; Gutierrez B; Ramirez AG; Hughes DC
    Support Care Cancer; 2022 Dec; 31(1):33. PubMed ID: 36517621
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
    Graeser M; Gluz O; Biehl C; Ulbrich-Gebauer D; Christgen M; Palatty J; Kuemmel S; Grischke EM; Augustin D; Braun M; Potenberg J; Wuerstlein R; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Ni H; Kolberg-Liedtke C; Feuerhake F; Kreipe HH; Nitz U; Harbeck N
    Clin Cancer Res; 2023 Feb; 29(4):805-814. PubMed ID: 36441798
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Establishment and validation of a LC-MS/MS method for the determination of anlotinib in human plasma: Application to therapeutic drug monitoring.
    Yu M; Liang Z; Xiong L; Liu F; Cheng L; Jia C; Qi X; Sun F
    Biomed Chromatogr; 2022 Dec; 36(12):e5501. PubMed ID: 36082703
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer.
    Ilgun AS; Aktepe F; Gonullu O; Kapucuoglu N; Yararbas K; Alco G; Ozturk A; Elbuken Celebi F; Erdogan Z; Ordu C; Unal C; Duymaz T; Soybir G; Yavuz E; Tuzlali S; Ozmen V
    Future Oncol; 2022 Sep; 18(29):3289-3298. PubMed ID: 36017739
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. "A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring".
    Soledad Poetto A; Posocco B; Zanchetta M; Gagno S; Orleni M; Canil G; Alberti M; Puglisi F; Toffoli G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Sep; 1207():123403. PubMed ID: 35940043
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative breast cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
    Gluz O; Nitz U; Kolberg-Liedtke C; Prat A; Christgen M; Kuemmel S; Mohammadian MP; Gebauer D; Kates R; Paré L; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Wuerstlein R; Graeser M; Pelz E; Jóźwiak K; Zu Eulenburg C; Kreipe HH; Harbeck N;
    Clin Cancer Res; 2022 Nov; 28(22):4995-5003. PubMed ID: 35797219
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of breast cancer Subtypes.
    Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
    Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy.
    Okcu O; Öztürk SD; Öztürk Ç; Şen B; Yasin Aİ; Bedir R
    Ann Diagn Pathol; 2022 Jun; 58():151930. PubMed ID: 35245821
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Anticancer Potential of silibinin Loaded Polymeric Nanoparticles against breast cancer Cells: Insight into the Apoptotic Genes Targets.
    Pourgholi A; Dadashpour M; Mousapour A; Firouzi Amandi A; Zarghami N
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2587-2596. PubMed ID: 34452574
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Uncovering Barriers to Screening for Distress in Patients With cancer via Machine Learning.
    Günther MP; Kirchebner J; Schulze JB; Götz A; von Känel R; Euler S
    J Acad Consult Liaison Psychiatry; 2022; 63(2):163-169. PubMed ID: 34438098
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Deep learning-based predictive biomarker of pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer.
    Li F; Yang Y; Wei Y; He P; Chen J; Zheng Z; Bu H
    J Transl Med; 2021 Aug; 19(1):348. PubMed ID: 34399795
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative breast cancer.
    Candelaria RP; Spak DA; Rauch GM; Huo L; Bassett RL; Santiago L; Scoggins ME; Guirguis MS; Patel MM; Whitman GJ; Moulder SL; Thompson AM; Ravenberg EE; White JB; Abuhadra NK; Valero V; Litton J; Adrada BE; Yang WT
    Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S35-S41. PubMed ID: 34272161
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.